Clinical Trials Logo

Clinical Trial Summary

To date, the diagnosis of telomeropathies is based on telomere length measured in blood cells. However, this type of analysis is not always sufficient because some mutations underlying the development of telomeropathies are not associated with abnormal shortened telomeres. Since telomere dysfunction analysis cannot be performed on blood cells, it is mandatory to have access to another cellular material. To date, skin biopsies are performed to obtain fibroblasts. However, this technique is relatively invasive. The aim of this project is to assess whether nasal epithelial cells obtained through nasal brushing could offer the opportunity to detect cellular alterations and mutations involved in telomeropathies, in a mildly invasive way. If successful, this technique could become a non-invasive clinical tool for the diagnosis work-up of telomeropathies. Moreover, investigators aim to assess whether olfactory function is impaired in patients with telomeropathies.


Clinical Trial Description

Endpoint #1: To assess the suitability of nasal brushing analyses for the diagnosis of telomeropathies. To date, the complete diagnosis of telomeropathies, including the identification of responsible mutations, is based on blood samples and fibroblast cultures obtained through skin biopsies. Cells obtained through nasal brushing offer the opportunity to detect cellular alterations and mutations involved in telomeropathies, in a mildly invasive way. Investigators will thus assess a population of patients with a suspicion of telomeropathy, using a nasal brushing, and will compare their nasal brushing results to those of age-matched healthy controls. In patients, results of nasal brushing will be compared to standard of care blood test (leukocyte telomere length using Flow-FISH technique). If investigators confirm that the nasal brushing offers the opportunity to i) detect damaged telomeres and premature cellular senescence and ii) identify mutations related to telomeropathies, this technique could become a non-invasive clinical tool for the diagnosis work-up of telomeropathies. Endpoint #2: To develop primary cell cultures for the functional study of new germline mutations. To date, various germline mutations have already been identified in telomeropathy patients, in a total of 17 genes. Understanding how these mutations were affecting telomere biology relied on in vitro studies with either patient-derived fibroblasts or engineered human cell lines recapitulating the mutation. This was a mandatory step towards the molecular understanding of these pathologies. Because olfactory neural precursors have the capacity to grow in culture, this offers the additional possibility to perform functional studies on primary cultures of nasal brushing-derived cells for novel mutations, with still unknown impact on telomeres, that would be identified. Again, this could advantageously replace patients' fibroblast cultures established through skin biopsy. Endpoint #3: To evaluate whether patients with telomeropathies have impaired olfactory function. Olfactory function is decreased in several diseases and is increasingly recognized as an indicator of biological aging. To date, no data exist regarding the impact of telomeropathies on olfactory function. Therefore, investigators aim to psychophysically assess olfactory function in patients with telomeropathies, in comparison to age-matched healthy controls. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05508321
Study type Interventional
Source Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Contact Caroline Huart, MD, PhD
Phone +3227646005
Email caroline.huart@saintluc.uclouvain.be
Status Recruiting
Phase N/A
Start date October 1, 2022
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04638517 - The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis Phase 2
Completed NCT02844478 - Stress-Busting Program and QoL, Bio-markers of Immunity/Stress and Cellular Aging N/A
Completed NCT04763525 - Efficacy of Pythagorean Self-Awareness for Aging Biomarkers Improvement, in T2D Patients and Healthy Individuals. N/A
Active, not recruiting NCT02299245 - Rosuvastatin Effect on Telomere-telomerase System in ACS Phase 4
Not yet recruiting NCT03710356 - Evaluating Efficacy and Safety of Danazol in Severe Hematologic or Pulmonary Disease Related to Telomeropathy Phase 1/Phase 2
Completed NCT03982589 - Telomere Length in Relation to Acute Stress Response in Critical Care Patients
Not yet recruiting NCT06430073 - Effect of Infections and Global DNA Methylation on Frailty Trajectories in Hospitalized Older Patients (INFRAGEN)
Not yet recruiting NCT05978921 - Physical Exercise in Patients With Schizophrenia N/A
Terminated NCT05715372 - Genetic Evaluation and Modification of Lifestyles to Improve Female Life Expectancy N/A
Active, not recruiting NCT03286699 - Lifestyle Change for Better Health N/A
Not yet recruiting NCT05598359 - TA-65 and Aging Associated Microvascular Dysfunction N/A
Recruiting NCT06056375 - Biological and Behavioral Outcomes of Community Nature Walks Phase 1
Completed NCT02055456 - Nandrolone Decanoate in the Treatment of Telomeropathies Phase 1/Phase 2
Recruiting NCT04211714 - Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure Phase 1
Completed NCT03459053 - CBART: The Reduction of Psychological and Physiological Stress in Women Undergoing IVF N/A